Literature DB >> 19103778

Proinflammatory response of human osteoblastic cell lines and osteoblast-monocyte interaction upon infection with Brucella spp.

M Victoria Delpino1, Carlos A Fossati, Pablo C Baldi.   

Abstract

The ability of Brucella spp. to infect human osteoblasts and the cytokine response of these cells to infection were investigated in vitro. Brucella abortus, B. suis, B. melitensis, and B. canis were able to infect the SaOS-2 and MG-63 osteoblastic cell lines, and the first three species exhibited intracellular replication. B. abortus internalization was not significantly affected by pretreatment of cells with cytochalasin D but was inhibited up to 92% by colchicine. A virB10 mutant of B. abortus could infect but not replicate within osteoblasts, suggesting a role for the type IV secretion system in intracellular survival. Infected osteoblasts produced low levels of chemokines (interleukin-8 [IL-8] and macrophage chemoattractant protein 1 [MCP-1]) and did not produce proinflammatory cytokines (IL-1beta, IL-6, and tumor necrosis factor alpha [TNF-alpha]). However, osteoblasts stimulated with culture supernatants from Brucella-infected human monocytes (THP-1 cell line) produced chemokines at levels 12-fold (MCP-1) to 17-fold (IL-8) higher than those of infected osteoblasts and also produced IL-6. In the inverse experiment, culture supernatants from Brucella-infected osteoblasts induced the production of IL-8, IL-1beta, IL-6, and TNF-alpha by THP-1 cells. The induction of TNF-alpha and IL-1beta was largely due to granulocyte-macrophage colony-stimulating factor produced by infected osteoblasts, as demonstrated by inhibition with a specific neutralizing antibody. This study shows that Brucella can invade and replicate within human osteoblastic cell lines, which can directly and indirectly mount a proinflammatory response. Both phenomena may have a role in the chronic inflammation and bone and joint destruction observed in osteoarticular brucellosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19103778      PMCID: PMC2643642          DOI: 10.1128/IAI.01259-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

Review 1.  Brucella intracellular life: from invasion to intracellular replication.

Authors:  Jean Pierre Gorvel; Edgardo Moreno
Journal:  Vet Microbiol       Date:  2002-12-20       Impact factor: 3.293

Review 2.  Invasion and intracellular trafficking of Brucella abortus in nonphagocytic cells.

Authors:  J Pizarro-Cerdá; E Moreno; J P Gorvel
Journal:  Microbes Infect       Date:  2000-06       Impact factor: 2.700

3.  Staphylococcus aureus infection of mouse or human osteoblasts induces high levels of interleukin-6 and interleukin-12 production.

Authors:  K L Bost; W K Ramp; N C Nicholson; J L Bento; I Marriott; M C Hudson
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

4.  Essential role of the VirB machinery in the maturation of the Brucella abortus-containing vacuole.

Authors:  D J Comerci; M J Martínez-Lorenzo; R Sieira; J P Gorvel; R A Ugalde
Journal:  Cell Microbiol       Date:  2001-03       Impact factor: 3.715

5.  GTPases of the Rho subfamily are required for Brucella abortus internalization in nonprofessional phagocytes: direct activation of Cdc42.

Authors:  C Guzmán-Verri; E Chaves-Olarte; C von Eichel-Streiber; I López-Goñi; M Thelestam; S Arvidson; J P Gorvel; E Moreno
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

6.  Monocyte chemoattractant protein-1 expression by osteoblasts following infection with Staphylococcus aureus or Salmonella.

Authors:  K L Bost; J L Bento; C C Petty; L W Schrum; M C Hudson; I Marriott
Journal:  J Interferon Cytokine Res       Date:  2001-05       Impact factor: 2.607

7.  Induction of colony-stimulating factor expression following Staphylococcus or Salmonella interaction with mouse or human osteoblasts.

Authors:  K L Bost; J L Bento; J K Ellington; I Marriott; M C Hudson
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

Review 8.  Acute septic arthritis.

Authors:  Mark E Shirtliff; Jon T Mader
Journal:  Clin Microbiol Rev       Date:  2002-10       Impact factor: 26.132

9.  Differential regulation of chemokine secretion in tuberculous and staphylococcal osteomyelitis.

Authors:  Kathleen M Wright; Jon S Friedland
Journal:  J Bone Miner Res       Date:  2002-09       Impact factor: 6.741

10.  Clinical findings, therapeutic approach, and outcome of brucellar vertebral osteomyelitis.

Authors:  Juan D Colmenero; Juan D Ruiz-Mesa; Antonio Plata; Pilar Bermúdez; Patricia Martín-Rico; María I Queipo-Ortuño; José M Reguera
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

View more
  31 in total

1.  Potential role of fibroblast-like synoviocytes in joint damage induced by Brucella abortus infection through production and induction of matrix metalloproteinases.

Authors:  Romina Scian; Paula Barrionuevo; Guillermo H Giambartolomei; Emilio A De Simone; Silvia I Vanzulli; Carlos A Fossati; Pablo C Baldi; M Victoria Delpino
Journal:  Infect Immun       Date:  2011-07-05       Impact factor: 3.441

2.  Temporal Role for MyD88 in a Model of Brucella-Induced Arthritis and Musculoskeletal Inflammation.

Authors:  Carolyn A Lacey; William J Mitchell; Charles R Brown; Jerod A Skyberg
Journal:  Infect Immun       Date:  2017-02-23       Impact factor: 3.441

3.  Phasevarion-Regulated Virulence in the Emerging Pediatric Pathogen Kingella kingae.

Authors:  Yogitha N Srikhanta; Ka Yee Fung; Georgina L Pollock; Vicki Bennett-Wood; Benjamin P Howden; Elizabeth L Hartland
Journal:  Infect Immun       Date:  2017-11-17       Impact factor: 3.441

4.  Brucella canis is an intracellular pathogen that induces a lower proinflammatory response than smooth zoonotic counterparts.

Authors:  Carlos Chacón-Díaz; Pamela Altamirano-Silva; Gabriela González-Espinoza; María-Concepción Medina; Alejandro Alfaro-Alarcón; Laura Bouza-Mora; César Jiménez-Rojas; Melissa Wong; Elías Barquero-Calvo; Norman Rojas; Caterina Guzmán-Verri; Edgardo Moreno; Esteban Chaves-Olarte
Journal:  Infect Immun       Date:  2015-10-05       Impact factor: 3.441

Review 5.  Pathogenesis and immunobiology of brucellosis: review of Brucella-host interactions.

Authors:  Paul de Figueiredo; Thomas A Ficht; Allison Rice-Ficht; Carlos A Rossetti; L Garry Adams
Journal:  Am J Pathol       Date:  2015-04-17       Impact factor: 4.307

6.  Interaction of Brucella abortus with Osteoclasts: a Step toward Understanding Osteoarticular Brucellosis and Vaccine Safety.

Authors:  Omar H Khalaf; Sankar P Chaki; Daniel G Garcia-Gonzalez; Larry J Suva; Dana Gaddy; Angela M Arenas-Gamboa
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

7.  Chlamydia pneumoniae and osteoporosis-associated bone loss: a new risk factor?

Authors:  M Di Pietro; G Schiavoni; V Sessa; F Pallotta; G Costanzo; R Sessa
Journal:  Osteoporos Int       Date:  2012-11-16       Impact factor: 4.507

8.  CXCR2 Mediates Brucella-Induced Arthritis in Interferon γ-Deficient Mice.

Authors:  Carolyn A Lacey; Lauren L Keleher; William J Mitchell; Charles R Brown; Jerod A Skyberg
Journal:  J Infect Dis       Date:  2016-03-06       Impact factor: 5.226

9.  Brucella abortus induces the secretion of proinflammatory mediators from glial cells leading to astrocyte apoptosis.

Authors:  Clara García Samartino; M Victoria Delpino; Clara Pott Godoy; María Silvia Di Genaro; Karina A Pasquevich; Astrid Zwerdling; Paula Barrionuevo; Patricia Mathieu; Juliana Cassataro; Fernando Pitossi; Guillermo H Giambartolomei
Journal:  Am J Pathol       Date:  2010-01-21       Impact factor: 4.307

10.  Pathogenic potential of Escherichia coli clinical strains from orthopedic implant infections towards human osteoblastic cells.

Authors:  Lise Crémet; Alexis Broquet; Bénédicte Brulin; Cédric Jacqueline; Sandie Dauvergne; Régis Brion; Karim Asehnoune; Stéphane Corvec; Dominique Heymann; Nathalie Caroff
Journal:  Pathog Dis       Date:  2015-09-01       Impact factor: 3.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.